Aberdeen Group plc Purchases 551,412 Shares of Dyne Therapeutics, Inc. $DYN
Aberdeen Group plc significantly increased its stake in Dyne Therapeutics, Inc. by 99%, adding 551,412 shares to now own 1,108,145 shares valued at $21.675 million. This institutional buying activity comes alongside a director's purchase of 3,000 shares, bringing insider ownership to 14.14%. Despite a recent EPS miss, analysts maintain a "Moderate Buy" rating with a consensus price target of $35.14 for Dyne Therapeutics.
A Look At Dyne Therapeutics (DYN) Valuation After Strong Recent Share Price Momentum
Dyne Therapeutics (DYN) has seen significant share price momentum, with a 26.8% return over the past month and a 127.5% return over the past year. Despite being a clinical-stage, loss-making company with a market value of $3.1 billion, its Price-to-Book ratio of 3.2x is lower than peers but higher than the broader US biotech industry average. A discounted cash flow model suggests the stock is trading at an 85% discount to its estimated future cash flow value of $126.01, indicating a potentially large valuation gap.
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
Dyne Therapeutics has filed a US$40.81 million shelf registration for an employee stock ownership plan and is preparing for potential launches in Duchenne muscular dystrophy and myotonic dystrophy type 1, focusing on payer engagement. This reiterates the company's high-risk, no-revenue investment narrative, with the shelf registration indicating continued dilution risk alongside strong share price gains. Dyne's efforts to translate clinical data into market access are crucial for its equity story, though its shares might still be overvalued.
Tax-driven share sale by Dyne (DYN) CFO Lucera Erick disclosed
Dyne Therapeutics, Inc.'s CFO, Lucera Erick, sold 5,727 shares of common stock at a weighted average price of $18.64 per share. This sale was automatically executed to cover tax withholding obligations related to restricted stock units that vested on March 31, 2025, and was conducted under a pre-established Rule 10b5-1 plan. Following this non-discretionary transaction, Erick retains 125,373 shares, including 114,575 unvested restricted stock units.
Dyne uses AMCP to make its case for DMD and DM1 patient access
Dyne Therapeutics will present three posters at the AMCP 2026 Annual Conference, focusing on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). These presentations, including data from DELIVER and ACHIEVE trials and a DM1 health insurance literacy study, aim to inform managed care access decisions for potential future drug launches. Dyne anticipates a potential DMD launch in the US next year and a DM1 launch in early 2028, and is engaging with payers to highlight the benefits of their investigational therapeutics.
SG Americas Securities LLC Invests $5.19 Million in Dyne Therapeutics, Inc. $DYN
SG Americas Securities LLC recently invested $5.19 million in Dyne Therapeutics, Inc. by purchasing 265,384 shares, representing a new stake in the company. Analysts generally rate Dyne Therapeutics as a "Moderate Buy" with an average target price of $35.14, and insider Brian S. Posner also increased his stake by purchasing additional shares. The company, a clinical-stage biotechnology firm focused on rare diseases, has a market capitalization of $2.99 billion and institutional investors own 96.68% of its stock.
What Dyne Therapeutics (DYN)'s ESOP Shelf Filing and Payer-Focused Launch Prep Means For Shareholders
Dyne Therapeutics (DYN) recently filed a US$40.81 million shelf registration for an employee stock ownership plan and is focusing on payer engagement and launch preparations for Duchenne and myotonic dystrophy treatments. This move reinforces dilution risk but also highlights their commercialization strategy, aiming to translate clinical data into market access. Investor opinions on Dyne's valuation are divided, given its status as a high-risk, late-stage rare disease platform with no revenue and a notable cash burn.
Dyne Therapeutics Announces Participation at 2026 Academy of Managed Care Pharmacy (AMCP) Conference to Begin Shaping Access in US for Potential Neuromuscular Medicines
Dyne Therapeutics will participate in the 2026 AMCP Annual Conference to discuss access strategies for its potential neuromuscular medicines, focusing on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company will present three posters detailing positive clinical trial results for zeleciment rostudirsen in DMD and zeleciment basivarsen in DM1, alongside research on health insurance literacy for DM1 patients. Dyne aims to engage with payers to contextualize the clinical benefits and expedite access for these therapeutics, anticipating potential launches in 2027 and early 2028.
DYN SEC Filings - Dyne Therapeutics, Inc. 10-K, 10-Q, 8-K Forms
This page provides comprehensive access to Dyne Therapeutics Inc.'s (DYN) official regulatory documents filed with the U.S. Securities and Exchange Commission, including 10-K, 10-Q, and 8-K forms. It highlights the company's focus on genetically driven neuromuscular diseases and details how these filings offer insights into its programs, financing, and risks. The platform also offers AI-powered summaries to help users quickly understand key points from these lengthy documents.
Dyne Therapeutics Announces Participation at 2026 Academy
Dyne Therapeutics will present three posters at the AMCP 2026 Annual Conference, focusing on Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company aims to prepare for potential US launches of its neuromuscular medicines in 2027 and 2028 by engaging with payers to highlight the benefits of its investigational therapeutics. This participation helps contextualize clinical trial results for managed care experts and ensures access decisions reflect patient needs.
Director at Dyne Therapeutics (DYN) adds 2,000 common shares
Dyne Therapeutics director Brian S. Posner reported an open-market purchase of 2,000 shares of common stock at a weighted average price of $17.08 per share. This transaction increases his direct holdings to 15,500 shares. The purchase, valued at $34,160, signals a positive sentiment from the insider regarding the company's prospects.
[144] Dyne Therapeutics, Inc. SEC Filing
This article reports on a recent SEC Form 144 filing by Dyne Therapeutics, Inc. A Form 144 indicates an intent to sell restricted securities without public registration. The filing details the proposed sale of 5,727 shares of common stock by Stifel Nicolaus & Company Inc. on April 1, 2026, which were acquired through restricted stock units as equity compensation.
Myotonic Dystrophy (DM) Clinical Trial Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | AMO Pharma, Lupin, Harmony Biosciences
DelveInsight's report highlights significant expansion in the Myotonic Dystrophy (DM) clinical trial pipeline, with over 20 pharmaceutical companies actively developing 22+ novel therapies. Key players like Lupin, Harmony Biosciences, and Arrowhead Pharmaceuticals are progressing drug candidates through various clinical stages, including Phase III, Phase II, and Phase I, targeting muscle stiffness and genetic mechanisms of DM. This indicates a robust and evolving landscape for Myotonic Dystrophy treatment.
Technical Reactions to DYN Trends in Macro Strategies
The article provides a technical analysis of Dyne Therapeutics Inc. (NYSE: DYN), indicating a strong overweight bias across all time horizons. It highlights an exceptional 73.0:1 risk-reward setup, targeting a 22.8% gain versus 0.3% risk. The analysis also details institutional trading strategies, including position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Dyne Therapeutics Stock Slides After Rally Fizzles
Dyne Therapeutics (DYN) stock is experiencing a pullback as traders take profits after a recent sharp rally, creating a "sell-the-news" event. This decline is attributed to concerns over the company's significant cash burn and a larger-than-expected annual net loss, despite progress in its DELIVER and ACHIEVE programs towards a Q2 2026 BLA filing. Technical sell signals and rising trading volumes on down days are further reinforcing the stock's slide.
Clearbridge Small Cap Growth Strategy Added Dyne Therapeutics (DYN) in Q4
ClearBridge Small Cap Growth Strategy added Dyne Therapeutics (DYN) to its portfolio in Q4 2025, recognizing the company's potential in developing RNA-based therapies for muscular dystrophy. Despite the strategy's underperformance in Q4 2025, it maintains optimism for small-cap growth stocks in 2026. Dyne Therapeutics, a clinical-stage neuromuscular disease company, had a market capitalization of $2.98 billion as of March 26, 2026, and showed significant share price gains over the past year.
Vanguard disaggregates holdings; Dyne Therapeutics (NASDAQ: DYN) shows 0 ownership
The Vanguard Group has filed an amended Schedule 13G/A for Dyne Therapeutics (NASDAQ: DYN), reporting zero beneficial ownership of the company's common stock. This change is due to an internal realignment effective January 12, 2026, where Vanguard's subsidiaries will now report their holdings separately. The filing confirms Vanguard itself no longer holds shares in Dyne Therapeutics.
Raymond James reiterates Strong Buy on Dyne Therapeutics stock
Raymond James has reiterated a Strong Buy rating and a $40.00 price target for Dyne Therapeutics (NASDAQ:DYN) stock, suggesting over 100% potential upside. This endorsement follows positive preliminary Phase 1 clinical data from Sarepta Therapeutics and other favorable analyst feedback on Dyne's clinical programs. Dyne Therapeutics is making significant strides in its clinical trials, particularly for myotonic dystrophy type 1, drawing positive attention from the investment community.
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts
Dyne Therapeutics (NASDAQ:DYN) has an average "Moderate Buy" rating from seventeen analysts, with a consensus 12-month target price of $35.14. Despite missing Q4 earnings estimates, several analysts have reiterated buy or strong-buy ratings. Insider activity shows a director recently increasing his stake, and institutional ownership remains high.
Raymond James reiterates Strong Buy on Dyne Therapeutics stock
Raymond James has reiterated a Strong Buy rating and a $40.00 price target for Dyne Therapeutics (NASDAQ:DYN), suggesting over 100% upside from its current price. This positive outlook follows preliminary Phase 1 clinical data for Sarepta Therapeutics’ SRP-1003 program in myotonic dystrophy type 1, with Raymond James highlighting Dyne's superior muscle tissue concentration achievements. Other firms like Baird, Jones Trading, and Stifel also maintain positive ratings, citing clinical progress in Duchenne muscular dystrophy and favorable Phase 3 study designs.
Dyne Therapeutics, Inc. $DYN Shares Bought by JPMorgan Chase & Co.
JPMorgan Chase & Co. increased its holdings in Dyne Therapeutics, Inc. by 9% in the third quarter, acquiring an additional 278,466 shares and bringing its total ownership to 3,365,245 shares valued at approximately $42.6 million. Other institutional investors have also modified their stakes in DYN, which has a MarketBeat consensus rating of "Moderate Buy" and a target price of $35.14. Additionally, Director Brian S. Posner recently purchased 3,000 shares, increasing his personal holdings to 11,500 shares.
MDA 2026: Dyne advances DMD therapy z-rostudirsen toward approval
Dyne Therapeutics is progressing its investigational exon-skipping therapy, z-rostudirsen, for Duchenne muscular dystrophy (DMD) toward regulatory approval. Recent data from the Phase 1/2 DELIVER trial presented at the MDA 2026 conference showed increased dystrophin levels, trends in functional improvement, and potential stabilization of heart and lung function in boys with DMD. Dyne plans to seek accelerated U.S. approval for z-rostudirsen based on these findings and will launch a Phase 3 trial to confirm the clinical benefits for full approval.
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma
The Myotonic Dystrophy Pipeline 2026 report by DelveInsight highlights over 20 companies and 22+ therapies in development for Myotonic Dystrophy. Notable companies like Dyne Therapeutics and Avidity Biosciences are advancing therapies, with recent updates including a partial clinical hold on PepGen's FREEDOM2-DM1 trial and Breakthrough Therapy Designation for Dyne's DYNE-101. The report covers various clinical phases, mechanisms of action, and routes of administration, alongside market drivers and barriers for Myotonic Dystrophy treatment.
Myotonic Dystrophy Pipeline 2026: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Dyne Therapeutics, Avidity Biosciences, Harmony Biosciences, AMO Pharma
DelveInsight's "Myotonic Dystrophy Pipeline Insight, 2026" report details the ongoing development of over 22 Myotonic Dystrophy treatment therapies by more than 20 companies. The report highlights emerging therapies like EF-210, ARO-DM1, VX-670, PGN-EDODM1, and Delpacibart etedesiran which are in various stages of clinical trials. Recent developments include a partial clinical hold on PepGen's FREEDOM2-DM1 trial, publication of Avidity Biosciences' MARINA® clinical trial findings in The New England Journal of Medicine, and Breakthrough Therapy Designation for Dyne Therapeutics' DYNE-101.
MDA 2026: Dyne therapy boosts strength, cognition in DM1
Dyne Therapeutics' zeleciment basivarsen (z-basivarsen), previously known as DYNE-101, has shown promising results in Phase 1/2 clinical trials for myotonic dystrophy type 1 (DM1), improving motor function and cognition. These findings support the initiation of a global Phase 3 study, HARMONIA, aiming for accelerated approval in the US. The therapy targets the underlying genetic defect in DM1 by clearing problematic RNA clumps, leading to reductions in disease burden and enhanced daily independence for patients.
Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?
Dyne Therapeutics has initiated its Phase 3 HARMONIA trial for myotonic dystrophy type 1 and released 24-month data for its Duchenne muscular dystrophy treatment, despite reporting a significant net loss of US$446.21 million in 2025. The company's investment case is strengthened by FDA alignment on the HARMONIA trial and multiple regulatory designations, emphasizing its focus on functional outcomes for rare disease patients. However, the substantial net loss and varied fair value estimates from the Simply Wall St Community highlight the ongoing financial risks and the critical need for flawless trial execution and continued access to capital.
Braidwell LP Sells 542,868 Shares of Dyne Therapeutics, Inc. $DYN
Braidwell LP reduced its stake in Dyne Therapeutics by 16.6%, selling over half a million shares. Concurrently, a director, Brian S. Posner, increased his holdings by purchasing 3,000 shares. Despite institutional selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $35.14, although the company recently missed EPS estimates and projects negative full-year EPS.
Integral Health Asset Management LLC Buys New Position in Dyne Therapeutics, Inc. $DYN
Integral Health Asset Management LLC has acquired a new stake in Dyne Therapeutics, Inc. (NASDAQ:DYN), purchasing 800,000 shares valued at approximately $10.12 million. This investment represents about 0.56% ownership of the company. Additionally, Director Brian S. Posner increased his holdings by purchasing 3,000 shares, bringing his total to 11,500 shares, while other institutional investors also adjusted their positions in the clinical-stage biotech firm.
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
Dyne Therapeutics is making significant progress in its rare disease pipeline, particularly for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). The company plans an accelerated application for its DMD drug, aiming for a 2027 launch, and has initiated a Phase 3 trial for its DM1 drug. These developments, along with positive long-term data for its DMD treatment, are increasing investor interest in Dyne Therapeutics, though the company faces risks such as ongoing losses and potential shareholder dilution.
Dyne Therapeutics DMD And DM1 Progress Sharpens Rare Disease Investment Case
Dyne Therapeutics is making significant strides in its rare disease pipeline, particularly with its Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) programs. The company plans an accelerated application for its DMD drug for a potential early 2027 launch, has completed enrollment for its DM1 Phase 1/2 trial, and started a Phase 3 trial for DYNE-101 in DM1. These developments, along with positive long-term data for its DMD treatment, have led to increased investor attention and a substantial rise in stock performance.
Fund tied to Dyne Therapeutics (DYN) director sells stock
A fund indirectly linked to Dyne Therapeutics director Dirk Kersten, ForDyne B.V., sold 129,672 shares of common stock at a weighted average price of $19.5151 per share. The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, ForDyne B.V. still holds 4,644,386 Dyne Therapeutics shares, with Kersten disclaiming beneficial ownership except for his pecuniary interest.
Director buys 2,000 Dyne Therapeutics (DYN) shares in open market
Dyne Therapeutics director Brian S. Posner purchased 2,000 shares of the company's common stock on March 11, 2026, at a price of $19.35 per share in an open-market transaction. This purchase increased his direct holdings to 13,500 shares. The transaction was detailed in an SEC Form 4 filing, indicating a positive sentiment for the company.
Insider Buying: Brian Posner Acquires Additional Shares of Dyne Therapeutics Inc (DYN)
Brian Posner, a Director at Dyne Therapeutics Inc (DYN), recently purchased 2,000 shares, increasing his total holdings to 13,500 shares. This transaction, dated March 11, 2026, reflects a broader trend where Posner has bought 5,000 shares over the past year without any sales. Despite overall insider selling for DYN, this acquisition signals confidence in the company, whose shares were trading at $19.35 with a market cap of $2.957 billion at the time of the purchase.
Dyne Therapeutics (DYN) Shares Key Details For Pivotal. Drugs
Dyne Therapeutics (NASDAQ:DYN) has provided key updates on its DMD and DM1 programs, announcing plans for an accelerated application for its DMD drug targeting a Q1 2027 launch and completing Phase 1/2 enrollment for DM1. Morgan Stanley noted the programs are on track but reduced its price target to $47 from $50 while maintaining an Overweight rating. The company is a biotechnology firm specializing in neuromuscular disease treatments.
Assessing Dyne Therapeutics (DYN) Valuation After Phase 3 HARMONIA Launch And New DELIVER Data
Dyne Therapeutics (DYN) has launched its Phase 3 HARMONIA trial for myotonic dystrophy type 1 and released new data from its Duchenne program. Despite recent share price volatility, a Discounted Cash Flow (DCF) model suggests Dyne is significantly undervalued at $130.41 per share compared to its current price of $18.06, factoring in its long-term potential as a loss-making clinical-stage biotech. Investors should weigh this potential upside against clinical trial risks and the company's current unprofitable status.
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate, Shares Surge 11.8%
Dyne Therapeutics (DYN) reported a Q4 2025 loss of $0.73 per share, which was narrower than the estimated $0.76 and represented a 4.4% improvement sequentially. Despite being a clinical-stage company with zero revenue, its shares surged 11.8% to $19.78 on positive investor sentiment regarding the narrowing loss trajectory and a strong cash position of $893.4 million, reflecting a net cash of $724.2 million. The company's focus remains on advancing its drug development pipeline with research and development expenses totaling $95.4 million for the quarter.
Brian Posner Purchases 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock
Director Brian Posner recently purchased 3,000 shares of Dyne Therapeutics (NASDAQ:DYN) stock for $45,180, increasing his stake by 35% to 11,500 shares. This insider buying follows positive cardiopulmonary data from the DELIVER trial and the initiation of the pivotal Phase III HARMONIA trial, which are seen as significant catalysts. Analysts maintain a "Moderate Buy" consensus rating for DYN, with an average price target of $36.13, and the company boasts a strong cash runway into mid-2028.
Director adds Dyne Therapeutics (DYN) shares in open-market purchase
Dyne Therapeutics director Brian S. Posner purchased 3,000 shares of common stock in an open-market transaction on March 6, 2026. The shares were acquired at a weighted average price of $15.06 per share, with prices ranging from $14.96 to $15.12. Following this transaction, Posner directly owns a total of 11,500 shares in the company.
Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade
Dyne Therapeutics (DYN) saw its stock price rise by 11.8% after Jefferies reiterated a "buy" rating and a $50 price target, suggesting a 153% upside potential. This comes after Dyne Therapeutics announced the initiation of the Phase 3 HARMONIA trial for its DM1 therapy candidate, zeleciment basivarsen, following positive Phase 2 results. The trial aims to assess functional improvement in DM1 patients using a "sit-to-stand" test as a primary endpoint.
Dyne Therapeutics (DYN) Q4 Loss Narrows to $0.73/Share vs $0.76 Estimate; Shares Surge 19%
Dyne Therapeutics (DYN) reported a Q4 2025 loss of $0.76 per share, which was narrower than the estimated $0.76 loss, leading to a 19.0% surge in its shares. The clinical-stage biotech posted no revenue and experienced a negative operating cash flow of $111.8 million, but ended the quarter with a strong cash position of $893.4 million. The company's Q4 loss marks the fourth consecutive quarter of narrowing losses, and investors are keenly awaiting upcoming clinical trial readouts for its muscle disease therapies.
Jefferies Maintains Buy on Dyne Therapeutics (DYN) March 2026
Jefferies has reiterated a "Buy" rating on Dyne Therapeutics (DYN) on March 9, 2026, expressing 70-80%+ confidence in an accelerated approval by Q1 2027. This decision did not include a new price target but signals continued analyst conviction in Dyne's clinical path. The market reacted with a 5.14% price increase following the note, highlighting investor attention to regulatory news.
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has initiated the Phase 3 HARMONIA trial for z-basivarsen (DYNE-101) in individuals with myotonic dystrophy type 1 (DM1). This global, randomized, placebo-controlled study will assess the multi-system efficacy, safety, and tolerability of the drug, enrolling approximately 150 participants aged 16 and older. The trial's design, including its primary endpoint of the five times sit to stand (5xSTS) test, has been aligned with the FDA and is intended to support traditional approval in the U.S. and ex-U.S. marketing applications.
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced new positive cardiopulmonary results from its DELIVER clinical trial of zeleciment rostudirsen (z-rostudirsen) for Duchenne muscular dystrophy (DMD). The 24-month data showed improvements in heart and lung function, specifically Force Vital Capacity Percent Predicted (FVC%p) and circumferential strain, compared to expected declines in natural history. These findings highlight the potential broad benefits of z-rostudirsen, attributing the success to its FORCE platform's ability to deliver therapeutics to various muscle tissues, including the heart, trunk, diaphragm, and CNS.
Dyne Therapeutics (NASDAQ:DYN) Trading 11.2% Higher - Time to Buy?
Dyne Therapeutics (NASDAQ:DYN) saw its stock jump 11.2% to $16.52 on Monday, though trading volume was light. Analysts have mixed views, with a consensus of "Moderate Buy" and an average price target of $36.13, despite the company remaining unprofitable with a Q EPS of -$0.76. Institutional ownership is high at 96.7%, and the company maintains a strong liquidity profile.
Dyne Therapeutics (DYN) Is Down 8.0% After Advancing Key Neuromuscular Trials Has The Bull Case Changed?
Dyne Therapeutics recently initiated a Phase 3 trial for myotonic dystrophy type 1 and reported positive long-term data for Duchenne muscular dystrophy, reinforcing its multi-asset approach in neuromuscular diseases. Despite these advancements, the stock experienced an 8.0% decline, highlighting that clinical execution risks and funding needs remain central to the company's investment narrative. The company's significant annual loss and varying fair value estimates from the Simply Wall St Community underscore the importance of upcoming clinical catalysts and financial stability.
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy
Dyne Therapeutics announced highly positive cardiopulmonary results from their DELIVER clinical trial of z-rostudirsen for Duchenne muscular dystrophy (DMD). New analyses out to 24 months showed improvements in heart and lung function, including forced vital capacity and cardiac performance indicators, compared to expected declines in natural history data. These findings expand on previous reports of improved muscle function and highlight the potential breadth of benefits from z-rostudirsen, attributing the success to the company's FORCE platform.
Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD)
Dyne Therapeutics announced positive cardiopulmonary results from its Phase 1/2 DELIVER clinical trial of z-rostudirsen in Duchenne muscular dystrophy (DMD) patients. New 24-month analyses showed improvements in both heart and lung function, specifically FVC%p and cardiac performance, contrasting with expected declines in natural history. These findings complement earlier reports of functional muscle improvement and suggest broad therapeutic benefits for z-rostudirsen.
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has initiated its Phase 3 HARMONIA trial for z-basivarsen (DYNE-101) in Myotonic Dystrophy Type 1 (DM1), aiming to enroll approximately 150 patients. The trial is designed to assess the drug's efficacy, safety, and tolerability, with the primary endpoint being the change in the five times sit to stand (5xSTS) test at week 49. This trial is aligned with FDA requirements for traditional U.S. approval and will support ex-U.S. marketing applications.
Dyne DMD trial shows better breathing, heart health after 24 months
Dyne Therapeutics reported positive 24-month cardiopulmonary data from its Phase 1/2 DELIVER trial of z-rostudirsen (DYNE-251) for Duchenne muscular dystrophy (DMD). The drug showed improvements in FVC%p, circumferential strain, and left ventricular ejection fraction compared to expected natural-history declines. While the market reacted negatively with a 3.28% decline for DYN, the safety profile remained favorable with mostly mild-to-moderate side effects.
Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1)
Dyne Therapeutics has initiated a Phase 3 HARMONIA trial for z-basivarsen in individuals with myotonic dystrophy type 1 (DM1). This global, randomized, placebo-controlled study will assess the multi-system efficacy, safety, and tolerability of z-basivarsen, with the primary endpoint focusing on the five times sit to stand (5xSTS) test. The trial design has been aligned with the FDA and is intended to support traditional approval in the U.S. and ex-U.S. marketing applications.
